India’s Sharp Increase In Type 2 Diabetes Boon To Drug Makers
This article was originally published in PharmAsia News
Executive Summary
Makers of drugs for diabetics report a 17 percent increase in sales in the 12-month period ending in August. Diabetic drugs also have increased from 4.6 percent of the drug market in India to 5.1 percent, according to ORG IMS. The increase, according to authorities, is due to the fact India has the world's largest population of diabetics, particularly Type 2 diabetes, which is expected to afflict more than 60 million people by 2017, up from 28 million last year. The numbers have led to an increasing number of drug makers entering that sector of the market, with GlaxoSmithKline expected to launch the first molecule for treatment within two years. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.